2018 Annual Meeting | C122 - Multiple Sclerosis Overview III: The Pathogenesis of Multiple Sclerosis and Mechanism of Action of Treatments for MS

Date Tuesday 04/24/18

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Michael K. Racke, MD, Olaf Stuve, MD, PhD, FAAN

Topic(s)

Learning Objectives Participants should be able to identify steps in MS pathogenesis, treatments used in MS management, and how approved therapies affect the immune response and potential complications resulting from those interventions.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Didactic, Interactive, Audience Participation

Event Timeline
03:30 PM - 05:30 PM	Speaker	MS Pathogenesis and Mechanism of MS Therapies Olaf Stuve, MD, PhD, FAAN, Gregory F. Wu, MD, FAAN

Faculty Disclosures
Michael K. Racke, MD	Dr. Racke has received personal compensation for serving as an employee of Quest Diagnostics. Dr. Racke has stock in Quest Diagnostics. Dr. Racke has received intellectual property interests from a discovery or technology relating to health care.
Olaf Stuve, MD, PhD, FAAN	Dr. Stuve has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Stuve has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Stuve has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Therapeutic Advances in Neurological Diseases. Dr. Stuve has received research support from US Department of Veterans Affairs. Dr. Stuve has received research support from National Multiple Sclerosis Society (US). Dr. Stuve has received research support from Merck KGaA.
Gregory F. Wu, MD, FAAN	Dr. Wu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Progentec. Dr. Wu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Wu has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Neuroimmunology. Dr. Wu has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Department of Justice.

��ɫ��

��ɫ��